Intellect Neurosciences, Inc. Issues Letter to Shareholders - GlobeNewswire press release
Shire is developing OX1 as a treatment for Friedreich's Ataxia and possibly other diseases for which OX1 may qualify for orphan drug designation.
Friedreich Ataxia and close related scientific news. Topics related to rare diseases.